Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years
We prospectively studied the incidence of cytomegalovirus (CMV) retinitis in 93 patients treated with highly active antiretroviral therapy (HAART) containing a protease inhibitor (PI), during a median follow-up period of 24 months. The median initial CD4+ count was 22 cells/microl (range, 1-311 cell...
Gespeichert in:
| Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 1999-11, Vol.22 (3), p.228-234 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 234 |
|---|---|
| container_issue | 3 |
| container_start_page | 228 |
| container_title | Journal of acquired immune deficiency syndromes (1999) |
| container_volume | 22 |
| creator | Labetoulle, M Goujard, C Frau, E Rogier, H Niessen, F Furlan, V Lantz, O Lecointe, D Delfraissy, J F Offret, H |
| description | We prospectively studied the incidence of cytomegalovirus (CMV) retinitis in 93 patients treated with highly active antiretroviral therapy (HAART) containing a protease inhibitor (PI), during a median follow-up period of 24 months. The median initial CD4+ count was 22 cells/microl (range, 1-311 cells/microl), and the median plasma HIV viral load was 5.1 log10 copies/ml (range, 2.4-6.4 log10 copies/ml). The fundus was examined monthly in patients with a history of CMV retinitis or an initial CD4+ count |
| doi_str_mv | 10.1097/00042560-199911010-00003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69467849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>47795467</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-85277a8f4ed418fe646e29cd791901d75b7a0965774dd734cbf1e55349e6e2a33</originalsourceid><addsrcrecordid>eNpdkUtvEzEUhS1URB_wF5DForsp9vjaHneHokIrVWIDbC3HvkNdJeNge1Jl15-OQ9qqYnUfOufcK32EUM4uODP6M2MMeqlYx40xnDPOurZi4g054Qag08MAR62XveyAC3lMTku5Z4wrAPOOHHOmNRPQn5DHxa6mNf52q7SNeS40Y41TrLHQOFEXtm7yGOj1za8uTiP62oaNqxGnWmjN6PaLh1jv6Caniq5g893FZawpl8vW-xiwRVA3BZrm6tsxmraYaU936HJ5T96OblXww1M9Iz-_Xv1YXHe337_dLL7cdl70rHaD7LV2wwgYgA8jKlDYGx-04YbxoOVSO2aU1BpC0AL8cuQopQCDTeiEOCPnh9z2558ZS7XrWDyuVm7CNBerDCg9gGnCT_8J79Ocp_ab7YVQYBTs04aDyOdUSsbRbnJcu7yznNk9IvuMyL4gsv8QNevHp_x5ucbwynhgIv4CS0ONZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>233649643</pqid></control><display><type>article</type><title>Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Free E- Journals</source><source>Journals@Ovid Complete</source><creator>Labetoulle, M ; Goujard, C ; Frau, E ; Rogier, H ; Niessen, F ; Furlan, V ; Lantz, O ; Lecointe, D ; Delfraissy, J F ; Offret, H</creator><creatorcontrib>Labetoulle, M ; Goujard, C ; Frau, E ; Rogier, H ; Niessen, F ; Furlan, V ; Lantz, O ; Lecointe, D ; Delfraissy, J F ; Offret, H</creatorcontrib><description>We prospectively studied the incidence of cytomegalovirus (CMV) retinitis in 93 patients treated with highly active antiretroviral therapy (HAART) containing a protease inhibitor (PI), during a median follow-up period of 24 months. The median initial CD4+ count was 22 cells/microl (range, 1-311 cells/microl), and the median plasma HIV viral load was 5.1 log10 copies/ml (range, 2.4-6.4 log10 copies/ml). The fundus was examined monthly in patients with a history of CMV retinitis or an initial CD4+ count <50 cells/microl and every 3 months in the other patients. Of patients with previously controlled CMV retinitis, 1 of 7 relapsed. In addition, 6 of 59 patients with a CD4+ count <50 cells/microl and no history of CMV retinitis before starting PI therapy developed CMV retinitis. Of them, 3 had at least one relapse during follow-up. CD4+ counts were <40 cells/microl at the time of primary or recurrent CMV retinitis, except in two cases (147 cells/microl and 203 cells/microl). In conclusion, the incidence of CMV retinitis was 0.091 per patient-year among study subjects with advanced HIV infection who were receiving HAART (95% confidence interval [CI], 0.037-0.145). The time to progression of CMV retinitis (mean, 215 days; 95% CI, 113-317 days) was longer than reported before widespread use of PIs.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/00042560-199911010-00003</identifier><identifier>PMID: 10770342</identifier><identifier>CODEN: JDSRET</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins Ovid Technologies</publisher><subject>Adult ; AIDS-Related Opportunistic Infections - drug therapy ; AIDS-Related Opportunistic Infections - epidemiology ; AIDS-Related Opportunistic Infections - immunology ; AIDS/HIV ; CD4 Lymphocyte Count ; Cytomegalovirus Retinitis - drug therapy ; Cytomegalovirus Retinitis - epidemiology ; Cytomegalovirus Retinitis - immunology ; Drug therapy ; Drug Therapy, Combination ; Epidemiology ; Eyes & eyesight ; Foscarnet - administration & dosage ; Foscarnet - therapeutic use ; Ganciclovir - administration & dosage ; Ganciclovir - therapeutic use ; HIV ; HIV Protease Inhibitors - administration & dosage ; HIV Protease Inhibitors - therapeutic use ; Human immunodeficiency virus ; Humans ; Incidence ; Indinavir - therapeutic use ; Infections ; Nelfinavir - therapeutic use ; Outcome Assessment (Health Care) ; Prospective Studies ; Reverse Transcriptase Inhibitors - administration & dosage ; Reverse Transcriptase Inhibitors - therapeutic use ; Ritonavir - therapeutic use ; Saquinavir - therapeutic use</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 1999-11, Vol.22 (3), p.228-234</ispartof><rights>Copyright Lippincott Williams & Wilkins Nov 1, 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-85277a8f4ed418fe646e29cd791901d75b7a0965774dd734cbf1e55349e6e2a33</citedby><cites>FETCH-LOGICAL-c320t-85277a8f4ed418fe646e29cd791901d75b7a0965774dd734cbf1e55349e6e2a33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10770342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Labetoulle, M</creatorcontrib><creatorcontrib>Goujard, C</creatorcontrib><creatorcontrib>Frau, E</creatorcontrib><creatorcontrib>Rogier, H</creatorcontrib><creatorcontrib>Niessen, F</creatorcontrib><creatorcontrib>Furlan, V</creatorcontrib><creatorcontrib>Lantz, O</creatorcontrib><creatorcontrib>Lecointe, D</creatorcontrib><creatorcontrib>Delfraissy, J F</creatorcontrib><creatorcontrib>Offret, H</creatorcontrib><title>Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>We prospectively studied the incidence of cytomegalovirus (CMV) retinitis in 93 patients treated with highly active antiretroviral therapy (HAART) containing a protease inhibitor (PI), during a median follow-up period of 24 months. The median initial CD4+ count was 22 cells/microl (range, 1-311 cells/microl), and the median plasma HIV viral load was 5.1 log10 copies/ml (range, 2.4-6.4 log10 copies/ml). The fundus was examined monthly in patients with a history of CMV retinitis or an initial CD4+ count <50 cells/microl and every 3 months in the other patients. Of patients with previously controlled CMV retinitis, 1 of 7 relapsed. In addition, 6 of 59 patients with a CD4+ count <50 cells/microl and no history of CMV retinitis before starting PI therapy developed CMV retinitis. Of them, 3 had at least one relapse during follow-up. CD4+ counts were <40 cells/microl at the time of primary or recurrent CMV retinitis, except in two cases (147 cells/microl and 203 cells/microl). In conclusion, the incidence of CMV retinitis was 0.091 per patient-year among study subjects with advanced HIV infection who were receiving HAART (95% confidence interval [CI], 0.037-0.145). The time to progression of CMV retinitis (mean, 215 days; 95% CI, 113-317 days) was longer than reported before widespread use of PIs.</description><subject>Adult</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>AIDS-Related Opportunistic Infections - epidemiology</subject><subject>AIDS-Related Opportunistic Infections - immunology</subject><subject>AIDS/HIV</subject><subject>CD4 Lymphocyte Count</subject><subject>Cytomegalovirus Retinitis - drug therapy</subject><subject>Cytomegalovirus Retinitis - epidemiology</subject><subject>Cytomegalovirus Retinitis - immunology</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Epidemiology</subject><subject>Eyes & eyesight</subject><subject>Foscarnet - administration & dosage</subject><subject>Foscarnet - therapeutic use</subject><subject>Ganciclovir - administration & dosage</subject><subject>Ganciclovir - therapeutic use</subject><subject>HIV</subject><subject>HIV Protease Inhibitors - administration & dosage</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Incidence</subject><subject>Indinavir - therapeutic use</subject><subject>Infections</subject><subject>Nelfinavir - therapeutic use</subject><subject>Outcome Assessment (Health Care)</subject><subject>Prospective Studies</subject><subject>Reverse Transcriptase Inhibitors - administration & dosage</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Ritonavir - therapeutic use</subject><subject>Saquinavir - therapeutic use</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkUtvEzEUhS1URB_wF5DForsp9vjaHneHokIrVWIDbC3HvkNdJeNge1Jl15-OQ9qqYnUfOufcK32EUM4uODP6M2MMeqlYx40xnDPOurZi4g054Qag08MAR62XveyAC3lMTku5Z4wrAPOOHHOmNRPQn5DHxa6mNf52q7SNeS40Y41TrLHQOFEXtm7yGOj1za8uTiP62oaNqxGnWmjN6PaLh1jv6Caniq5g893FZawpl8vW-xiwRVA3BZrm6tsxmraYaU936HJ5T96OblXww1M9Iz-_Xv1YXHe337_dLL7cdl70rHaD7LV2wwgYgA8jKlDYGx-04YbxoOVSO2aU1BpC0AL8cuQopQCDTeiEOCPnh9z2558ZS7XrWDyuVm7CNBerDCg9gGnCT_8J79Ocp_ab7YVQYBTs04aDyOdUSsbRbnJcu7yznNk9IvuMyL4gsv8QNevHp_x5ucbwynhgIv4CS0ONZQ</recordid><startdate>19991101</startdate><enddate>19991101</enddate><creator>Labetoulle, M</creator><creator>Goujard, C</creator><creator>Frau, E</creator><creator>Rogier, H</creator><creator>Niessen, F</creator><creator>Furlan, V</creator><creator>Lantz, O</creator><creator>Lecointe, D</creator><creator>Delfraissy, J F</creator><creator>Offret, H</creator><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>19991101</creationdate><title>Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years</title><author>Labetoulle, M ; Goujard, C ; Frau, E ; Rogier, H ; Niessen, F ; Furlan, V ; Lantz, O ; Lecointe, D ; Delfraissy, J F ; Offret, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-85277a8f4ed418fe646e29cd791901d75b7a0965774dd734cbf1e55349e6e2a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>AIDS-Related Opportunistic Infections - epidemiology</topic><topic>AIDS-Related Opportunistic Infections - immunology</topic><topic>AIDS/HIV</topic><topic>CD4 Lymphocyte Count</topic><topic>Cytomegalovirus Retinitis - drug therapy</topic><topic>Cytomegalovirus Retinitis - epidemiology</topic><topic>Cytomegalovirus Retinitis - immunology</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Epidemiology</topic><topic>Eyes & eyesight</topic><topic>Foscarnet - administration & dosage</topic><topic>Foscarnet - therapeutic use</topic><topic>Ganciclovir - administration & dosage</topic><topic>Ganciclovir - therapeutic use</topic><topic>HIV</topic><topic>HIV Protease Inhibitors - administration & dosage</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Incidence</topic><topic>Indinavir - therapeutic use</topic><topic>Infections</topic><topic>Nelfinavir - therapeutic use</topic><topic>Outcome Assessment (Health Care)</topic><topic>Prospective Studies</topic><topic>Reverse Transcriptase Inhibitors - administration & dosage</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Ritonavir - therapeutic use</topic><topic>Saquinavir - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Labetoulle, M</creatorcontrib><creatorcontrib>Goujard, C</creatorcontrib><creatorcontrib>Frau, E</creatorcontrib><creatorcontrib>Rogier, H</creatorcontrib><creatorcontrib>Niessen, F</creatorcontrib><creatorcontrib>Furlan, V</creatorcontrib><creatorcontrib>Lantz, O</creatorcontrib><creatorcontrib>Lecointe, D</creatorcontrib><creatorcontrib>Delfraissy, J F</creatorcontrib><creatorcontrib>Offret, H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Labetoulle, M</au><au>Goujard, C</au><au>Frau, E</au><au>Rogier, H</au><au>Niessen, F</au><au>Furlan, V</au><au>Lantz, O</au><au>Lecointe, D</au><au>Delfraissy, J F</au><au>Offret, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>1999-11-01</date><risdate>1999</risdate><volume>22</volume><issue>3</issue><spage>228</spage><epage>234</epage><pages>228-234</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><coden>JDSRET</coden><abstract>We prospectively studied the incidence of cytomegalovirus (CMV) retinitis in 93 patients treated with highly active antiretroviral therapy (HAART) containing a protease inhibitor (PI), during a median follow-up period of 24 months. The median initial CD4+ count was 22 cells/microl (range, 1-311 cells/microl), and the median plasma HIV viral load was 5.1 log10 copies/ml (range, 2.4-6.4 log10 copies/ml). The fundus was examined monthly in patients with a history of CMV retinitis or an initial CD4+ count <50 cells/microl and every 3 months in the other patients. Of patients with previously controlled CMV retinitis, 1 of 7 relapsed. In addition, 6 of 59 patients with a CD4+ count <50 cells/microl and no history of CMV retinitis before starting PI therapy developed CMV retinitis. Of them, 3 had at least one relapse during follow-up. CD4+ counts were <40 cells/microl at the time of primary or recurrent CMV retinitis, except in two cases (147 cells/microl and 203 cells/microl). In conclusion, the incidence of CMV retinitis was 0.091 per patient-year among study subjects with advanced HIV infection who were receiving HAART (95% confidence interval [CI], 0.037-0.145). The time to progression of CMV retinitis (mean, 215 days; 95% CI, 113-317 days) was longer than reported before widespread use of PIs.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins Ovid Technologies</pub><pmid>10770342</pmid><doi>10.1097/00042560-199911010-00003</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-4135 |
| ispartof | Journal of acquired immune deficiency syndromes (1999), 1999-11, Vol.22 (3), p.228-234 |
| issn | 1525-4135 1944-7884 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69467849 |
| source | MEDLINE; Journals@Ovid LWW Legacy Archive; Free E- Journals; Journals@Ovid Complete |
| subjects | Adult AIDS-Related Opportunistic Infections - drug therapy AIDS-Related Opportunistic Infections - epidemiology AIDS-Related Opportunistic Infections - immunology AIDS/HIV CD4 Lymphocyte Count Cytomegalovirus Retinitis - drug therapy Cytomegalovirus Retinitis - epidemiology Cytomegalovirus Retinitis - immunology Drug therapy Drug Therapy, Combination Epidemiology Eyes & eyesight Foscarnet - administration & dosage Foscarnet - therapeutic use Ganciclovir - administration & dosage Ganciclovir - therapeutic use HIV HIV Protease Inhibitors - administration & dosage HIV Protease Inhibitors - therapeutic use Human immunodeficiency virus Humans Incidence Indinavir - therapeutic use Infections Nelfinavir - therapeutic use Outcome Assessment (Health Care) Prospective Studies Reverse Transcriptase Inhibitors - administration & dosage Reverse Transcriptase Inhibitors - therapeutic use Ritonavir - therapeutic use Saquinavir - therapeutic use |
| title | Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T16%3A02%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytomegalovirus%20retinitis%20in%20advanced%20HIV-infected%20patients%20treated%20with%20protease%20inhibitors:%20incidence%20and%20outcome%20over%202%20years&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=Labetoulle,%20M&rft.date=1999-11-01&rft.volume=22&rft.issue=3&rft.spage=228&rft.epage=234&rft.pages=228-234&rft.issn=1525-4135&rft.eissn=1944-7884&rft.coden=JDSRET&rft_id=info:doi/10.1097/00042560-199911010-00003&rft_dat=%3Cproquest_cross%3E47795467%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=233649643&rft_id=info:pmid/10770342&rfr_iscdi=true |